For businesses, Supreme Court ruling provides a measure of clarity in health care calculations
The Supreme Court decision largely upholding President Obama’s health care overhaul was the talk of the business world Thursday. But executives weren’t speaking with one voice. Biotechnology leaders hailed a provision creating a regulatory pathway for generic versions of their medicines while also protecting the original drug makers for a longer period. But medical device executives said a tax that will help pay for the law will cost device makers $29 billion over the coming decade, sapping funds for research and hiring workers.